Introduction. Cangrelor is a direct and reversible P2Y12 receptor antagonist that inhibits platelet activation and aggregation, currently approved in adults undergoing percutaneous coronary intervention. Aims. To characterise the PKPD relationship of cangrelor and provide a basis for extrapolating efficacy from adults to infants and children, as well as defining the dose rationale in these populations. […]
